Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)

Show other versions (1)

Background The relevance of the cause of kidney disease to prognosis among patients with chronic kidney disease is uncertain. Study Design Observational study. Settings and Participants 6,245 nondialysis participants in the Study of Heart and Renal Protection (SHARP). Predictor Baseline cause of kid...

書目詳細資料
Main Authors:	Haynes, R, Staplin, N, Emberson, J, Herrington, W, Tomson, C, Agodoa, L, Tesar, V, Levin, A, Lewis, D, Reith, C, Baigent, C, Landray, M
格式:	Journal article
出版:	2014

相似書籍

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
由: Haynes, R, et al.
出版: (2014)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
由: Staplin, N, et al.
出版: (2015)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
由: Herrington, WG, et al.
出版: (2023)

Smoking and adverse outcomes in patients With CKD: the Study of Heart and Renal Protection (SHARP)
由: Emberson, J, et al.
出版: (2016)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
由: Staplin, N, et al.
出版: (2016)

Conventional and genetic evidence on the association between adiposity and CKD
由: Zhu, P, et al.
出版: (2020)

Impact of CKD on household income
由: Morton, R, et al.
出版: (2017)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
由: Herrington, W, et al.
出版: (2016)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
由: Lamprea-Montealegre, J, et al.
出版: (2019)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
由: Zhu, P, et al.
出版: (2020)

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
由: Herrington, W, et al.
出版: (2014)

Evidence for the prevention and treatment of stroke in dialysis patients
由: Herrington, W, et al.
出版: (2014)

Effects of lowering LDL cholesterol on progression of kidney disease.
由: Haynes, R, et al.
出版: (2014)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
由: Mihaylova, B, et al.
出版: (2019)

Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
由: Baigent, C, et al.
出版: (2010)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
由: Reith, C, et al.
出版: (2017)

Impact of CKD on Household Income
由: Rachael L. Morton, et al.
出版: (2018-05-01)

Benefits of lowering cholesterol in chronic kidney disease Reply
由: Baigent, C, et al.
出版: (2011)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
由: Mafham, M, et al.
出版: (2017)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
由: Storey, B, et al.
出版: (2018)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
由: C. Reith, et al.
出版: (2017-05-01)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
由: Herrington, W, et al.
出版: (2018)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
由: Herrington, W, et al.
出版: (2022)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
由: Schlackow, I, et al.
出版: (2017)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
由: Zhu, P, et al.
出版: (2020)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
由: Mayne, K, et al.
出版: (2024)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
由: Storey, B, et al.
出版: (2017)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
由: Mayne, KM, et al.
出版: (2024)

Study of Heart and Renal Protection (SHARP).
由: Baigent, C, et al.
出版: (2003)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
由: Baigent, C, et al.
出版: (2011)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
由: Baigent, C, et al.
出版: (2011)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
由: Staplin, N, et al.
出版: (2022)

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
由: Cholesterol Treatment Trialists' Collaboration, et al.
出版: (2016)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
由: Haynes, R, et al.
出版: (2018)

Serum free light chains and the risk of ESRD and death in CKD.
由: Haynes, R, et al.
出版: (2011)

Serum free light chains and the risk of ESRD and death in CKD
由: Haynes, R, et al.
出版: (2011)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
由: Mayne, K, et al.
出版: (2023)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
由: Staplin, N, et al.
出版: (2021)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
由: Staplin, N, et al.
出版: (2023)

Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study.
由: Landray, M, et al.
出版: (2010)